NEW YORK, NY / ACCESS Newswire / February 11, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and ...

Guggenheim lowered the firm’s price target on Regeneron (REGN) to $950 from $1,200 and keeps a Buy rating on the shares. The firm, which is ...

Dividend stocks can be terrific investments. The best ones provide investors with passive income and upside potential. Over ...

Real-time index price for KBW Finsec Dividend Yield Index (KDX), along with buy or sell indicators, analysis, charts, historical performance, news and more ...

Investors were feeling zen on Wednesday, with no major news about Donald Trump's tariffs to worry about ahead of the monthly ...

Since abrdn's acquisition in 2023, HQL has delivered a total return of 25.5%, though its price appreciation has been modest.

Real-time index price for KBW Finsec Dividend Yield Index (KDX), along with buy or sell indicators, analysis, charts, historical performance, news and more ...

Regenxbio's gene therapy faces market challenges as Goldman Sachs lowers its rating and price target, citing competition and ...

This Fund seeks to track the performance of the Index, a widely recognised benchmark of U.S. stock market performance that is comprised of the stocks of large U.S. companies. The Fund employs a ...

View the most recent dividend declared by the scheme in the last 30 days along with its value.